French researchers who used F-18 FDG-PET/CT found that only complete metabolic response to treatment without abnormal FDG uptake, not initial tumor or node staging, significantly predicted two-year progression-free survival and cause-specific survival among patients with anal cancer. The findings in the Journal of Nuclear Medicine also showed that FDG-PET/CT yielded 92% sensitivity, 85% specificity, 72% positive predictive value and 96% negative predictive value in detecting residual tumors and led to care management changes in 16% of patients, prompting researchers to say the modality shows potential for post-treatment follow-up of anal cancer.
F-18 FDG-PET/CT shows promise in assessing anal cancer treatment response
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.